Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

Pharmacogenomics - 1 Jul 2012

Mitra Amit K, Kirstein Mark N, Khatri Amit, Skubitz Keith M, Dudek Arkadiusz Z, Greeno Edward W, Kratzke Robert A, Lamba Jatinder K

Abstract excerpt

AIM: The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy. MATERIALS & METHODS: SNPs within nine gemcitabine pathway genes, namely CDA, CMPK, DCK, DCTD, NT5C2, NT5C3, SLC28A1, SLC28A3 and SLC29A1 were analyzed for association with gemcitabine pharmacokinetics. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Metabolic Networks and Pathways

Share to Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 22838949
DOI: 10.2217/pgs.12.81

Genes

CDA
DCK
DCTD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.PMID 22838949Read ↗

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Semantic proximity Read ↗

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.Semantic proximity Read ↗

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.Semantic proximity Read ↗

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.Semantic proximity Read ↗

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Semantic proximity Read ↗

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Semantic proximity Read ↗

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.